STATE OF ANTIBIOTICS RESISTANCE OF KLEBSIELLA PNEUMONIAE

Cover Page


Cite item

Full Text

Abstract

Klebsiella pneumoniae microorganisms belong to a group of the most prevalent clinically significant pathogens with a high level of antibacterial resistance (ESKAPE). The speed of formation of antibiotics-resistance by K. pneumoniae strains has sharply increased and reached pandemic scale. One of the main clinically significant mechanisms of antimicrobial resistance is (3-lactamase production, the groups being active depending on the region, country' and hospital. Currently, a significant part of nosocomial K. pneumoniae is resistant to penicillins, 11I-IV generation cephalosporins. The growth of resistance of klebsiellae to carbapenems is a serious threat to the healthcare system. First ofall, KPC-, OXA-, NDM-, VIM-, IMP-producing Widespread of carbapenem-resistant klebsiellae gives evidence on the necessity of international collaboration within the framework of antibiotics resistance control. An increase of frequency of obtained resistance of K. pneumoniae to non-(3-lactame antibiotics (fluoroquinolones, aminoglycosides) is noted. Isolates of K. pneumoniae resistant to tygecyclin, colistin are registered. In general, the problem of antibiotics resistance of causative agents of human diseases including K. pneumoniae continues to intensify. This is a serious threat to world public health that requires action in all sectors of the state.

About the authors

E. V. Anganova

Irkutsk State Medical Academy of Post-Graduate Education - Branch of Russian Medical Academy of Continuous Professional Education; Scientific Centre of Problems of Family Health and Human Reproduction

Author for correspondence.
Email: noemail@neicon.ru
Россия

A. V. Vetokhina

Irkutsk State Medical Academy of Post-Graduate Education - Branch of Russian Medical Academy of Continuous Professional Education; Irkutsk Regional Clinical Hospital

Email: noemail@neicon.ru
Россия

L. A. Raspopina

Irkutsk State Medical Academy of Post-Graduate Education - Branch of Russian Medical Academy of Continuous Professional Education; Irkutsk Regional Infectious Hospital

Email: noemail@neicon.ru
Россия

E. L. Kichigina

Irkutsk State Medical Academy of Post-Graduate Education - Branch of Russian Medical Academy of Continuous Professional Education

Email: noemail@neicon.ru
Россия

E. D. Savilov

Irkutsk State Medical Academy of Post-Graduate Education - Branch of Russian Medical Academy of Continuous Professional Education; Scientific Centre of Problems of Family Health and Human Reproduction

Email: noemail@neicon.ru
Россия

References

  1. Агеевец В.А. Молекулярная характеристика продуцентов рода Klebsiella в этиологической структуре бактериальных ОКИ, оценка их патогенности на уровне фено- и генотипа. Эпидемиология и вакцинопрофилактика. 2011,6 (61): 62-65.
  2. Анганова Е.В. Условно-патогенные энтеробактерии: до карбапенемаз семейства Enterobacteriaceae, выделенных в Санкт-Петербурге. Автореф. дис. канд. биол. наук. Санкт-Петербург, 2016.
  3. Анганова Е. В., Духанина А.В., Савилов Е.Д. Бактерииминирующие популяции, биологически свойства, медико-экологическая значимость. Автореф. дис. д-ра биол. наук. Иркутск, 2012.
  4. Богомолова Н.С., Большаков Л.В., Орешкина Т.Д., Кузнецова С.М. Динамика приобретенной резистентности к бета-лактамам антибиотикам основных грамотрицательных возбудителей инфекций в реконструктивной хирургии в 2004-2008 гг Антибиотики и химиотерапия. 2010, 1-2: 21-29.
  5. Гельфанд Б.Р., Белоцерковский Б.З., Милюкова И.А., Проценко Д.Н., Гельфанд Е.Б., Попов ТВ. Значение энтеробактерий в этиологии нозокомиальных инфекций у больных в критических состояниях. Современные возможности антимикробной терапии. Анналы хирургии. 2015, 4: 12-26.
  6. Ильина В.Н., Субботовская А.И., В.С. Козырева, Д.С. Сергеевичев, А.Н. Шилова Чувствительность энтеробактерий, выделенных в кардиохирургическом стационаре, к антимикробным препаратам. Патология кровообращения и кардиохирургия. 2013, 3: 40-44.
  7. Крыжановская О. А. Чувствительность к антибиотикам и механизмы устойчивости к карбапенемам Acinetobacterbaumannii, Pseudomonas aeruginosa и Klebsiella pneumoniae, выделенных у детей в отделениях реанимации и интенсивной терапии. Автореф. дисс. канд. мед.наук. М., 2016.
  8. Литвинова Т.И. Фармакоэномические аспекты антибактериальной терапии абсцедирующей пневмонии. Автореф. дисс. канд. мед. наук. Благовещенск, 2007.
  9. Маркелова Н.Н. Полиантибиотикорезистентность некоторых грамотрицательных бактерий и возможности ее преодоления с помощью эфирных масел. Автореф. дисс. канд. биол. наук. Пенза, 2016.
  10. Покудина И.О., Коваленко К.А. Распространенность и вклад в антибиотикоустойчивость р-лактамаз у амбулаторных изолятов Klebsiella pneumoniae. Международный журнал прикладных и фундаментальных исследований. 2016, 12 (2): 295-298.
  11. П.Решедько Г.К., Рябкова Е.Л., Кречекова О.И., Сухорукова М.В., Шевченко О.В., Эйделыптейн М.В., КозловР.С.Дуркутюков В.Б., Нехаева Г.И., Бочкарев Д.Н., Розанова С.М., Боронина Л.Г., Агапова Е.Д., Марусина Н.Е., Мултых И.Г., Тарабан В.К., Здзитовецкий Д.Э., Сарматова Н.И., Тихонов Ю.Г. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клиническая микробиология и антимикробная химиотерапия. 2008, 10 (2): 96-117.
  12. Рябкова Е.Л. Оптимизация антибиотикотерапии нозокомиальных инфекций, вызванных Klebsiella pneumoniae, в стационарах России. Автореф. дис. канд. мед. наук. Смоленск, 2006.
  13. Сухорукова М.В., Эйдельштейн М.В., СклееноваЕ.Ю., МванчикН.В., ТимоховаА.В., Дехнич А.В., Козлов Р.С., Попов Д.А., Астанина М.А., Жданова О.А., Болышева ГС., Болышева Г.С., Новикова Р.И., Валиуллина И.Р, Кокарева Т.С., Частоедова А.Н., Поликарпова С.В. Антибиотикорезистентность нозокомиальных штаммов Entero-bacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования (Марафон) в 2011-2012 гг. Клиническая микробиология и антимикробная химиотерапия. 2014, 16 (4): 254-265.
  14. Устойчивость к противомикробным препаратам. Информационный бюллетень ВОЗ. 2016. [http://www.who.int/mediacentre/factsheets/fsl 94/ru/].
  15. Antimicrobial resistance surveillance in Europe 2014. [http://ecdc.europa.eu/en/publica-tions/_layouts/forms/Publication_DispForm.aspx?Listr=4f55ad51 -4aed-4d32-b960-af70113dbb90&ID=1400].
  16. Ben-David D., Kordevani R., Keller N. et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin. Microbiol. Infect. 2012, 18 (1): 54-60.
  17. Boucher H., Talbot G., Benjamin D. et al. 10x20 Progress-Development of new drugs active against gram-negative bacilli: An update from the infectious diseases society of America. Clin. Infect. Dis. 2013, 56 (12): 1685-1694.
  18. Bradford P.A. Extended-spectrum lactamases in the 21st centure: characterization, epidemiology and detections of this important resistance threat. Clin. Microbio. Rev. 200 К 14 (4): 933-951.
  19. Bradford P.A., Bratu S., Urban C. et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 2004, 39: 55-60.
  20. Bratu S., Landman D., Haag R. et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 2005, 165: 1430-1435.
  21. Chen Y.T., Lin A.C., Kristopher S. et al. Sequence of closely related plasmids encoding bla(NDM-l ) in two unrelated Klebsiella pneumoniae isolates in Singapore. PLoS One. 2012, 7 (11): 48737. doi: 10.1371/journal.pone.0048737.
  22. Cornaglia G., Riccio M. L., Mazzariol A. et al. Appearance oflMP-1 metallo-beta-lactamase in Europe. Lancet. 1999, 353 (9156): 899-900.
  23. Cuzon G., Ouanich J., Gondret R. et al. Outbreak of ОХА-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob. Agents Chemother. 201 L 55(5): 2420-2423.
  24. Dowzicky M.J., Park C.H. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the tigecycline evaluation and surveillance trial (TEST) 2005 to 2007. Clin. Ther. 2008, 30 (11): 2040-2050.
  25. Doumith M., Ellington J. M., Livermore D.M. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacterspp. clinical isolates from the UK. J. Antimicrob. Chemother. 2009, 63 (4): 659-667.
  26. Enfield К. B., Huq N. N., Gosseling M. F. et al. Control of simultaneous outbreaks of carbap-enemase-producing Enterobacteriaceae and extensively drugresistant Acinetobacter bauman-nii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 carbapenemase-resistant Enterobacteriaceae toolkit. Infect. Control Hosp. Epidemiol. 2014, 35 (7): 810-817.
  27. Giakkoupi R, Xanthaki A., Kanelopoulou M. et al. VIM-1 Metallo-beta-lactamase producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. 2003, 41 (8): 3893-3896.
  28. Gupta N., Limbago В. M., Patel J. B. etal. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin. Infect. Dis. 2011, 53 (1): 60-67.
  29. Johnson A.P., Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-P-lactamase(NDM)-mediated carbapenem resistance. J. Med. Microbiol. 2013, 62: 499-513.
  30. Jaruratanasirikul S., Sudsai T. Korean network for study on infectious diseases (KONSID). Continuous increase of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean network for study on infectious diseases (KONSID). Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. Antimicrob. Chemother. 2009, 63 (3): 560-563.
  31. Kelland K. Last-line drug resistance poses «alarming» European health threat. Health News. 2014. [http://www.reuters.com/article/us-health-antibiotics-europe-idUSKCN-0J10W720141117].
  32. Lamoureaux T.L., Frase H., Antunes N.T. Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6. Antimicrob. Agents Chemother. 2012, 56 (11): 6006-6008.
  33. Lautenbach E., Fishman N.O., Bilker W.B. et al. Risk factors for of resistance to fluoroquinolones in nosocomial infections caused by Klebsiella pneumoniae and Escherichia coli. Arch. Intern. Med. 2002; 162: 2469-2477.
  34. Lin W. H. Clinical and microbiological characteristics of Klebsiella pneumoniae from community-acquired recurrent urinary tract infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33 (9): 1533-1539.
  35. Lim T.-R, Cal Y., Hong Y. et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2015, 59 (5): 2515-2524.
  36. Liu Y.Y., Wang Y., Walsh T.R. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 2016, 16 (2): 161-168.
  37. Norskov-Lauritsen N., Marchandin H., Dowzicky M. J. Antimicrobial susceptibility of tige-cycline and comparators against bacterial isolated collected as part of the TEST study in Europe (2004-2007). J. Antimicrob. Agents. 2009, 34 (2): 121-130.
  38. Osterblad M., Kirveskari J., Hakanen A.J. et al. Carbapenemase-producingEnterobacteriaceae in Finland: the first years (2008-2011). J. Antimicrob. Chemother. 2012, 67: 2860-2864.
  39. Papadimitriou-Olivgeris M., Marangos M., Fligou F. et al. KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality Diagn. Microb. Infect. Dis. 2013, 77:169-173.
  40. Peirano G., Ahmed-Bentley J., Fuller J. et al. Appearance of carbapenemases-producing gram-negative bacteria in Alberta (CANADA), due to the foreign trip: first 3 years of observation. JCM. 2014. [http://danies.ru/expert/14657/].
  41. Poirel L., Heritier C, Tolun V. et al. Emergence of oxacillinase mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2004, 48 (1): 15-22.
  42. Poole K. Efflux - mediated antimicrobial resistance. J. Antimicrob. Chemother. 2005, 56 (1): 20-51.
  43. SanchezG.V. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg. Infect. Dis. 2013, 19 (1): 133-136.
  44. Tzouvelekis L.S., Markogiannakis A.A., Psichogiou В M. et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an Evolving crisis of global dimensions. Clinical Microbiology. 2012, 25 (4): 682-707.
  45. Van der Bij A.K., Pitout J.D. The role of international travel in the worldwide spread of mul-tiresistant Enterobacteriaceae. J. Antimicrob. Chemother. 2012, 67: 2090-2100.
  46. Wailan A.M., Paterson D.L. The spread and acquisition of NDM-1: a multifactorial problem. Expert Rev. Anti. Infect. Ther. 2014, 12 (1): 91-115.
  47. WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO, 2017. [http://www.univadis.rU/medical-news/l 83/Nazvany-samye-opasnye-bakterii?utm_ source=newsletter+email&utm_medium=email&utm_campaign=medicaU-updates+-+daily&utm_content=J 297516&utm_term==autornated_daily].
  48. Yong D., Toleman M. A., Giske C. G. et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM -1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents. Chemother. 2009, 53 (12): 5046-5054.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Anganova E.V., Vetokhina A.V., Raspopina L.A., Kichigina E.L., Savilov E.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies